Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58


Light-Induced Length Shrinkage of Rod Photoreceptor Outer Segments.

Lu Y, Benedetti J, Yao X.

Transl Vis Sci Technol. 2018 Dec 21;7(6):29. doi: 10.1167/tvst.7.6.29. eCollection 2018 Nov.


Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T; GASTRIC group.

J Natl Cancer Inst. 2013 Nov 6;105(21):1600-7. doi: 10.1093/jnci/djt270. Epub 2013 Oct 9. Review.


Aphanomyces euteiches cell wall fractions containing novel glucan-chitosaccharides induce defense genes and nuclear calcium oscillations in the plant host Medicago truncatula.

Nars A, Lafitte C, Chabaud M, Drouillard S, Mélida H, Danoun S, Le Costaouëc T, Rey T, Benedetti J, Bulone V, Barker DG, Bono JJ, Dumas B, Jacquet C, Heux L, Fliegmann J, Bottin A.

PLoS One. 2013 Sep 23;8(9):e75039. doi: 10.1371/journal.pone.0075039. eCollection 2013.


Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.

Ann Oncol. 2013 Jul;24(7):1754-61. doi: 10.1093/annonc/mdt106. Epub 2013 Mar 22.


Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.

Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Slingluff CL Jr.

Clin Cancer Res. 2012 Jan 1;18(1):256-62. doi: 10.1158/1078-0432.CCR-11-1633. Epub 2011 Oct 5.


Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.

Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD.

J Clin Oncol. 2010 Aug 1;28(22):3611-6. doi: 10.1200/JCO.2009.25.8285. Epub 2010 Jul 6.


Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD.

J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.


Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.

Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL Jr.

Clin Trials. 2010 Aug;7(4):312-21. doi: 10.1177/1740774510374973. Epub 2010 Jul 1.


Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D.

J Clin Oncol. 2010 Jan 20;28(3):460-5. doi: 10.1200/JCO.2009.23.1407. Epub 2009 Dec 14.


Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J.

J Clin Oncol. 2009 Nov 20;27(33):5660-9. doi: 10.1200/JCO.2009.21.9022. Epub 2009 Oct 26. Review.


The value of physical performance tests for predicting therapy outcome in patients with subacute low back pain: a prospective cohort study.

Moradi B, Benedetti J, Zahlten-Hinguranage A, Schiltenwolf M, Neubauer E.

Eur Spine J. 2009 Jul;18(7):1041-9. doi: 10.1007/s00586-009-0965-1. Epub 2009 Apr 11.


End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A; ACCENT Group.

J Clin Oncol. 2007 Oct 10;25(29):4569-74. Epub 2007 Sep 17.


Cancer research training: the Southwest Oncology Group young investigator training program (YITP).

Nahleh Z, Komrokji R, Jazieh AR, Benedetti J, Sparks D.

J Cancer Educ. 2006 Summer;21(2):77-9.


Asynchronous communication among clinical researchers: a study for systems design.

Gennari JH, Weng C, Benedetti J, McDonald DW.

Int J Med Inform. 2005 Oct;74(10):797-807.


An ethnographic study of collaborative clinical trial protocol writing.

Gennari JH, Weng C, McDonald DW, Benedetti J, Green S.

Stud Health Technol Inform. 2004;107(Pt 2):1461-5.


Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.


Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.

Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup.

Ann Surg Oncol. 2002 Apr;9(3):278-86.


Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA.

N Engl J Med. 2001 Sep 6;345(10):725-30.


Alterations in exon 4 of the p53 gene in gastric carcinoma.

Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C.

Gastroenterology. 2000 Jun;118(6):1039-44.


Supplemental Content

Loading ...
Support Center